The tumor suppressor p53 is a multifunctional protein that plays a critical role in modulating cellular responses upon DNA damage or other stresses. These functions of p53 are regulated both by protein-protein interactions and phosphorylation. The double-stranded RNA activated protein kinase PKR is a serine/threonine kinase that modulates protein synthesis through the phosphorylation of translation initiation factor eIF-2a. PKR is an interferon (IFN)-inducible protein that is thought to mediate the anti-viral and anti-proliferative eects of IFN via its capacity to inhibit protein synthesis. Here we report that PKR physically associates with p53. The interaction of PKR with p53 is enhanced by IFNs and upon conditions that p53 acquires a wild type conformation. PKR/p53 complex formation in vitro requires the N-terminal regulatory domain of PKR and the last 30 amino acids of the C-terminus of human p53. In addition, p53 may function as a substrate of PKR since phosphorylation of human p53 on serine 392 is induced by activated PKR in vitro. These novel ®ndings raise the possibility of a functional interaction between PKR and p53 in vivo, which may account, at least in part, for the ability of each protein to regulate gene expression at both the transcriptional and the translational levels.
Introduction
In instances where a cell suers genotoxic stress as a result of exposure to radiation or chemicals, the cell must undergo growth arrest so that the damage can be repaired. In other cases, such as when the damage is too extensive, a process of programmed cell death known as apoptosis is initiated. In both cases the goal is to prevent the accumulation of cells that have undergone tumorigenic alterations. One of the most critical components involved in the induction of both growth arrest and apoptosis in response to DNA damage is the p53 tumor suppressor (Ko and Prives, 1996; Levine, 1997; White, 1996) .
Normally present at low levels in a cell, the onset of DNA damage or cellular stress causes the accumulation of p53 protein (Ko and Prives, 1996; Levine, 1997) . p53 then utilizes its capacity as a transcription factor to induce the expression of a number of genes that ultimately induce a state of cell cycle arrest at the G 1 phase. One such gene is the p21 WAF1/Cip1 inhibitor of cyclin dependent kinases (cdks) (El-Deiry et al., 1993; Harper et al., 1993) . The pro-apoptotic bax gene has been shown to be a transcriptional target for p53 and may be one of the ways by which p53 induces cell death via its function as a transcription factor (Miyashita and Reed, 1995) . However, p53-mediated apoptosis has been shown to occur in the absence of de novo protein and RNA synthesis (Caelles et al., 1994; White, 1996) .
One of the most striking aspects regarding the importance of p53 in the maintenance of genomic stability is that over half of all known human cancers contain mutations within the p53 gene (Pfeifer and Holmquist, 1997) . Additionally, mice with targeted deletions of the p53 gene develop normally but they are prone to developing spontaneous tumors at an early age (Ko and Prives, 1996) .
The double-stranded (ds) RNA-dependent protein kinase, termed PKR, is one of the best-characterized members of the interferon (IFN)-inducible family of proteins (Clemens and Elia, 1997) . PKR is a serinethreonine kinase that is present as a 68 kDa protein in humans and 65 kDa in mice. In the presence of dsRNA, PKR becomes activated through the process of autophosphorylation (Clemens and Elia, 1997) . Activated PKR then phosphorylates the a subunit of the translation initiation factor eIF-2 (Clemens and Elia, 1997), a modi®cation that causes inhibition of protein synthesis (Hershey, 1989) . It is in this manner that PKR has been suggested to play a role in the antiviral response induced by IFNs (Katze, 1995) .
The amino terminal half of PKR contains the dsRNA binding motifs, while the carboxy terminal half contains the 11 conserved domains found in all serine/threonine kinases (Clemens and Elia, 1997) . Elucidation of the structure of PKR allowed for further study for roles beyond that of mediating antiviral eects. For example, PKR has demonstrated antiproliferative and tumor suppressor activities in vitro. With regard to the former, wild type (wt) PKR has been shown to inhibit cell growth in mammalian cells and yeast (Chong et al., 1992; Koromilas et al., 1992) . In the latter case, mutants of PKR that are incapable of binding RNA but retain their catalytic activity cause transformation (Barber et al., 1995) . Similarly, mutations that render the protein catalytically inactive, but retaining dsRNA binding capacity, also cause transformation and tumorigenesis (Koromilas et al., 1992; Meurs et al., 1993) . These catalytically inactive mutants involve either a point mutation of an invariant lysine residue at position 296 in subdomain II to arginine (Katze et al., 1991) or deletion of six highly conserved amino acids leu 361 -pheile-gln-met-glu 366 within subdomain V (Koromilas et al., 1992) . Consistent with its putative role as a tumor suppressor, PKR has been shown to induce apoptosis (Lee and Esteban, 1994; Lee et al., 1997; Der et al., 1997; Takizawa et al., 1996; Yeung et al., 1996) . However, targeted deletion of the PKR gene does not cause spontaneous tumor formation in mice, arguing that inactivation of PKR may be necessary but not sucient for cell transformation in vivo (Yang et al., 1995) .
It is of interest to note that the activities of both PKR and p53 can be modulated through proteinprotein interactions. For example, dimerization of PKR is believed to play a role in regulating the activity of the kinase (Clemens and Elia, 1997) . Other proteins such as the 58 kDa cellular inhibitor of PKR (p58 IPK ), or the vaccina virus K3L protein can bind to PKR thus inhibiting its kinase activity and, in the case of overexpression of p58, cause transformation (Clemens and Elia, 1997). We have recently shown that PKR can modulate IFN signaling through the interaction with the STAT1 transcription factor (Wong et al., 1997) , indicating that PKR can form functional interactions with other proteins. The interaction of p53 with cellular and viral oncoproteins, such as mdm2 and the E1B 55 kDa protein, respectively, can inhibit p53 function and contribute to a transformed phenotype (Ko and Prives, 1996) . Conversely, the interaction with the CBP/p300 protein functions as a co-activator of p53 transcriptional activity (Avantaggiati et al., 1997; Gu et al., 1997; Lill et al., 1997) .
Other IFN-inducible proteins can exert their growth control eects by binding to and modulating the activity of proteins that play a crucial role in cell proliferation (Choubey and Lengyel, 1995; Datta et al., 1996; Min et al., 1996) . Based on this, we sought to examine whether PKR, as an IFN inducible protein, might interact with such proteins as a possible means of explaining the molecular mechanism(s) behind the ability of PKR to regulate cell growth.
Here, we report that PKR can interact with p53 both in vivo and in vitro. The interaction between PKR and p53 appears to be dependent on the conformation of p53 as PKR interacts better with p53 that is in a wild type rather than a mutant conformation. This interaction requires the amino terminal regulatory domain of PKR and the carboxy terminal basic domain of p53. Furthermore, we demonstrate that PKR can phosphorylate human p53 on serine 392 in vitro. These novel ®ndings may have important implications for a functional interaction between the two proteins in vivo in the regulation of gene expression at the transcriptional and translational levels. 3) and PKR 7/7 MEFs (lanes 4 and 5) before (lanes 2 and 4) or after treatment (lanes 3 and 5) with IFN-a/b (1000 IU/ml; 18 h) were immunoprecipitated with the monoclonal anti-p53 PAb421 antibody followed by immunoblot analysis with rabbit anti-sera to mouse PKR. Lane 1, whole cell extracts (WCE; 50 mg of protein) from NIH3T3 cells was used as a positive control to mouse PKR. The membrane was stripped and re-probed with rabbit anti-sera to p53 (lower panel)
Results

Co-immunoprecipitation of PKR and p53
The possible interaction of PKR with other cellular proteins was ®rst examined in extracts from untreated or IFN-b treated HeLa S3 cells. Treatment with IFN-b was used to upregulate PKR protein, which is due to the transcriptional activation of the PKR gene (Clemens and Elia, 1997) ( Figure 1a, bottom panel, lanes 1 and 2) . The ability of PKR to interact with the p53 tumor suppressor protein was tested by immunoprecipitation with monoclonal antibodies to p53 followed by immunoblotting with an anti-human PKR (13B8-F9) antibody. In these experiments, we noticed that a portion of PKR (*10% of cellular PKR) from IFN-b-treated cells extracts co-precipitated with p53 using the PAb421 antibody, which recognizes an epitope on the Cterminus of p53 ( Figure 1a, top panel, lane 4) . The p53 levels in HeLa S3 cells were detected by immunoblot analysis using rabbit anti-sera to p53 ( Figure 1a , middle panel, lanes 3 and 4). The lack of detectable p53 after immunoprecipitation with anti-human PKR antibody ( Figure 1a , middle panel, lane 2) was probably due to the low levels of p53 in HeLa S3 cells (Hoppe-Seyler and Butz, 1993) . Upregulation of PKR protein after IFN-b treatment ( Figure 1a , bottom panel, lane 2) may have accounted for the detectable amount of PKR that coprecipitated with p53 from HeLa S3 cells (Figure 1a , top panel, lane 4). Similar data were obtained when the antip53 PAb1801 antibody, which recognizes an epitope on the N-terminal domain of human p53, was used (data not shown).
To determine whether the association of PKR with p53 occurred in cells that were not transformed, we examined the interaction in mouse embryonic fibroblasts (MEFs) derived from PKR +/+ and PKR 7/7 mice (Yang et al., 1995) . In this experiment, cell extracts from untreated and IFN treated PKR +/+ and PKR 7/7 cells were ®rst immunoprecipitated with anti-p53 PAb421 antibody followed by immunoblotting with a polyclonal antibody that recognizes mouse PKR (TIK). The PKR/p53 complex was detected in cell extracts from PKR +/+ MEFs (Figure 1b (Wong et al., 1997) . These ®ndings indicate that association of PKR with p53 is not an IFN-dependent process nor it is due to a transformed phenotype. 7) were transiently transfected in COS-1 cells. Part of the whole cell extracts (WCE; 50 mg) was analysed for mutant PKR expression by immunoblot analysis with a monoclonal anti-human PKR antibody (13B8-F9; lanes 5 ± 7). The rest (500 mg of protein) was subjected to immunoprecipitation with the monoclonal antip53 antibody PAb421 (lanes 2 ± 4). The levels of co-immunoprecipitated PKR were detected by immunoblot analysis with the antihuman PKR 13B8-F9 antibody. As a control for PKR, whole cell extracts (50 mg of protein) from HeLa S3 cells were used in lane 1. Lanes 2 and 5, samples from mock transfected COS-1 cells. The membrane was stripped and re-probed with rabbit anti-sera to p53 to assay for p53 levels after immunoprecipitation (lower panel). (b) COS-1 cells were transiently transfected with 5 mg of wt p53 cDNA alone (lane 2), 5 mg of PKRK296R cDNA alone (lane 4) or 5 mg PKRK296R cDNA plus 5 mg wt p53 cDNA (lane 3). Protein extracts (500 mg) from mock transfected (lane 5), PKRK296R transfected (lane 4) or wt p53 and PKRK296R co-transfected cells (lane 3) were subjected to immunoprecipitation with 10 mg anti-human PKR antibody chemically coupled to agarose beads (lanes 3 ± 5). Immunoprecipitates were then analysed for p53 binding to PKR by immunoblotting with the monoclonal anti-p53 PAb1801 antibody. As control, protein extracts (50 mg) from mock transfected cells (lane 1) or wt p53 transfected cells (lane 2) were used for the immunoblot analysis with the anti-p53 PAb1801 antibody. The membrane was stripped and re-probed with anti-human PKR antibody to assess levels of PKRK296R (lower panel)
We next examined whether the catalytic activity of PKR was required for the interaction with p53. COS-1 cells were transiently transfected with either of the two catalytically inactive PKR mutants PKRD6 (Koromilas et al., 1992) or PKRK296R (Katze et al., 1991) . An interaction between the PKR mutants and the endogenous monkey p53 was detected by immunoprecipitation with the anti-p53 PAb421 antibody followed by immunoblotting with anti-human PKR antibody ( Figure 2a , top panel, lanes 3 and 4). The amount of PKR mutants that co-precipitated with the endogenous p53 was directly proportional to the levels of expression of these mutants (Figure 2a , top panel, compare lane 3 with 6, and 4 with 7). As a control for p53, the blot was stripped and re-probed with rabbit anti-sera to p53, which shows equal p53 levels ( Figure  2a , lower panel).
The interaction of p53 with PKRK296R was also detected in COS-1 cells when the immunoprecipitation-immunoblotting procedure was reversed ( Figure  2b ). After transfection with wtp53 ( Figure 2b 
PKR preferentially interacts with the wild type form of p53
It has been reported that the ability of p53 to interact with other proteins is dependent on the conformation of p53 (Avantaggiati et al., 1997) . We were interested in examining whether the interaction between PKR and p53 was conformation-dependent. To do so, we used baby rat kidney (BRK) cells co-expressing the temperature sensitive (ts) p53 (val135) mutant and either the adenovirus E1A (p53An1) or E1A plus the E1B 19K genes (19K1) (Debbas and White, 1993) . In this system, expression of the tsp53 in its mutant conformation at 378C is sucient to block apoptosis by E1A and permit transformation with high frequency. When p53 acquires a wild type conformation at 328C, E1A and p53 transformants undergo apoptosis. However, expression of the E1B 19K protein blocks p53-mediated apoptosis induced by E1A; instead the cells arrest at the G 1 phase (Debbas and White, 1993).
Formation of the PKR/p53 complex in BRK cells was examined by a combination of immunoprecipitation with anti-p53 PAb421 antibody followed by immunoblot analysis with rabbit anti-sera to mouse PKR ( Figure 3a , top panel). We found that the PKR/p53 interaction was induced upon conditions that p53 acquired wild type conformation. When the cells were switched from the restrictive to permissive temperatures in BRK cells that undergo either apoptosis ( Figure 3a , top panel, lanes 1 ± 4) or cell cycle arrest (Figure 3a , lanes 5 ± 8), the pKR/p53 complex reached maximum levels between 6 and 12 h after the temperature shift ( Figure 3a , top panel, lanes 3 and 4, 7 and 8). The protein levels of either p53 (Figure 3a , bottom panel) or PKR ( Figure 3b , top panel) did not change signi®cantly upon conditions that p53 acquired a wild type conformation. In both cell types, p21 expression was induced at 328C consistent with a transcriptionally active wild type conformation of p53 ( Figure  3b , middle panel). These ®ndings indicate that PKR exhibits a higher anity for binding to wild type than mutant form of p53, and that conformational changes of p53 may be critical for its interaction with PKR in vivo.
The N-terminal regulatory domain of PKR is required for the interaction with p53
We ®rst attempted to identify the region of PKR that interacted with p53. Using a GST fusion protein (val135) and adenovirus E1A protein (p53An1; lanes 1 ± 4) or E1A protein and adenovirus E1B protein (19K1; lanes 5 ± 8) were switched from 37 to 328C for the indicated periods of time. PKR/ p53 complex formation was detected by immunoprecipitation with the monoclonal anti-p53 PAb421 antibody followed by immunoblot analysis with either rabbit anti-sera to mouse PKR (TIK) (upper panel) or rabbit anti-sera to p53 (CM-1; lower panel). (b) PKR and p21 protein levels in 50 mg of protein extracts from the apoptotic p53An1 (lanes 1 ± 4) or G 1 arrested 19K1 cells (lanes 5 ± 8) were analysed by immunoblotting with rabbit anti-sera to mouse PKR (TIK) (top panels) or p21 (middle panels) and normalized to actin levels with the monoclonal antiactin C4 antibody (bottom panels) containing full length PKR (a.a. 1 ± 551, Figure 4 ), we were able to con®rm the interaction by doing a pulldown assay using Since both the N-terminus of PKR and p53 can bind to RNA (Clemens and Elia, 1997; Ko and Prives, 1996) we examined whether the interaction between PKR and p53 was dependent on RNA. This was accomplished by expressing a form of the N-terminus of PKR containing a mutant within the ®rst regulatory domain (RD1, Figure 4) ; Green et al., 1995) , as a GST fusion protein.
35 Slabeled p53 was able to interact with both wild type and the RNA-binding mutant of PKR (Figure 4 , lanes 7 and 8), suggesting that RNA may not be necessary for the interaction between the two proteins.
PKR interacts with the C-terminal basic domain of p53
We next wanted to map the domain of p53 required for the interaction with PKR. Initially we used GST-p53 fusion proteins consisting of the full length (a.a. 1 ± 393), the N-terminal transactivation domain (a.a. 1 ± 160), the DNA-binding domain (a.a. 160 ± 318) or the C-terminal domain of human p53 (a.a. 319 ± 393), as shown in the diagram in Figure 5a . These fusion proteins have been used previously to map the interaction between p53 and MDM2 and the TATAbinding protein (TBP), respectively (Chen et al., 1993; Horikoshi et al., 1995) . Pulldown experiments using these GST-p53 fusion proteins with 35 S-labeled in vitro translated PKR con®rmed not only an interaction with full length p53 (Figure 5a , lane 2), but revealed that the C-terminal domain consisting of amino acids 319 ± 393 is required for the interaction (Figure 5a, lane 5) .
The C-terminal domain consists of several subdomains that play an important role in p53 function (Ishioka et al., 1995) . Using the GST-p53 C-terminus fusion protein as a template, three truncated GST-p53 fusion proteins were generated (Figure 5b) . One encompasses the entire oligomerization domain (a.a. 319 ± 362); a second encompasses the b-strand of the oligomerization domain (a.a. 319 ± 337) and a third consists of the entire basic domain (a.a. 362 ± 393). Pulldown experiments using these GST-p53 fusion proteins with 35 S-labeled in vitro translated PKR showed that the basic domain of p53 is required for its interaction with PKR (a.a. 362 ± 393; Figure 5b , lane 5).
PKR phosphorylates p53 in vitro
The C-terminal domain of p53 contains several serine and threonine residues, and some of them are S-labeled in vitro translated p53 was added to full length GST-PKR (left panel, lane 2), GST ± PKR deletion mutants encompassing the wild type N-terminus (a.a. 1 ± 262; lanes 3 and 7), a form of the N-terminus containing a mutation that abolishes the ability of PKR to bind RNA (LS9; lane 8), the C-terminus (a.a. 263 ± 551; lane 4), or GST alone (lanes 5 and 9) coupled to glutathione sepharose beads. Following the pull down, the reactions were fractionated on SDS ± 10% PAGE and p53 was visualized by¯uorography 35 S-labeled in vitro translated PKR was incubated with the`full length' GST-p53 C-terminus fusion protein (a.a. 319 ± 393, lane 2), the various deletion mutants (a.a. 319 ± 362, 319 ± 337 or 362 ± 393; lanes 3 ± 5, respectively), or GST alone (lane 6) coupled to glutathione sepharose beads under rotation. After washings, the proteins were fractionated on SDS ± 12% PAGE and PKR was visualized by¯uorography modi®ed by phosphorylation (Steegenga et al., 1996) . Having observed that PKR can interact with the Cterminal domain of p53, we were interested in examining whether the C-terminus of p53 could serve as a substrate for PKR. The phosphorylation assays were performed by immunoprecipitating PKR from extracts derived from HeLa S3 cells after IFN-b treatment. Immunoprecipitated PKR was then activated by reovirus dsRNA, and phosphorylation was performed by adding puri®ed substrates together with [g-32 P]ATP. Under these conditions of the experiment, activated PKR was capable of inducing phosphorylation of eIF-2a in vitro (Figure 6a, lane 2) . In these experiments we also noticed that activation of PKR resulted in phosphorylation of two polypeptides (Figure 6a, lane 1) , one of *68 kDa, which represented full length autophosphorylated PKR, and the second of *48 kDa, which was likely a degradation product of autophosphorylated PKR as previously reported (Galabru and Hovanessian, 1987) . Similar experiments were then performed with puri®ed GST-p53 fusion proteins (Figure 6b , top panel). To better distinguish the phosphorylated forms of p53, at the end of the incubation period the GST-53 fusion proteins were isolated from the reaction mixtures by pulldown with glutathione-sepharose (Figure 6b , bottom panel). Activated PKR was capable of phosphorylating the GST-C-terminus p53 fusion protein (Figure 6b , top panel, lane 2), and this was more apparent when GST-p53 fusion proteins were pulled down by glutathione-sepharose beads ( Figure  6b , bottom panel, lane 2).
To identify the type of phosphorylation we performed phosphoamino acid analysis of the phosphorylated Cterminal domain of p53 (Boyle et al., 1991) . These experiments showed that the C-terminus of p53 was phosphorylated by PKR on serine residue(s) (Figure 7a ). There are seven serine residues within the C-terminal domain of p53 (Figure 7b ). To identify which of the serine(s) was phosphorylated by PKR, each of the individual serine residues was substituted for alanine by site directed mutagenesis. Puri®ed GST-p53 fusion proteins containing Ser-Ala mutations were then tested for phosphorylation by PKR as described above ( Figure  7b) . Of all the mutations, only the substitution of Ser 392 to Ala abolished phosphorylation of GST-p53 by PKR (Figure 7b, lane 12) suggesting that Ser 392 is a target of PKR in vitro.
We then examined whether phosphorylation of the C-terminus of p53 is directly mediated by PKR and not by a contaminating kinase in PKR immunoprecipitates from HeLa cells. To this end we used recombinant GST-wtPKR fusion protein for in vitro kinase assays (Figure 8a ). Addition of dsRNA to the kinase assays did not further induce GST-wtPKR activity (data not shown); consistent with previous reports showing that recombinant bacterially produced GST-wtPKR does not show a dsRNA dependence The kinase reactions were carried out at 308C for 30 min, and subjected to SDS ± 10% PAGE and autoradiography. (b) Phosphorylation of GST-p53 a.a. 319 ± 393 by PKR. Kinase assays were carried out as described previously in the absence (lane 1) or the presence of equal amounts (250 ng) of either puri®ed GST protein alone (lane 3) or puri®ed GST-p53 Cterminus fusion protein (lane 2). At the end of the incubation, reactions were either subjected to SDS ± 10% PAGE and autoradiography (upper panel) or pulled down with glutathione-sepharose, subjected to SDS ± 12% PAGE analysis and autoradiography (lower panel) and is constitutively active in vitro (Kumar et al., 1994; Rende-Fournier et al., 1997) . The activity and speci®city of GST-wtPKR was tested using puri®ed recombinant histidine-tagged wild type eIF-2a or eIF2a with a Ser 51 -Ala mutation, which abolished its phosphorylation by PKR (Zhu et al., 1996) (Figure  8a, lanes 3 and 4) . GST-wtPKR phosphorylated the wild type GST-p53 C-terminus fusion protein ( Figure  8a To further con®rm that phosphorylation of GSTp53 by PKR on serine 392 was mediated by PKR directly, we performed an in vitro kinase assay with GST-wtPKR and cold ATP (Figure 8b and c) . GSTp53 C-terminus (Figure 8b ) or GST-full-length p53 (Figure 8c ) was incubated with either GST (Figure 8b and c, lane 3) or GST-wtPKR (Figure 8, lane 4) . Immunoblotting with anti-phosphoserine 392 antibodies (Lu et al., 1998) showed phosphorylation of both the GST-p53 C-terminus and full-length GST-p53 by GSTwtPKR (Figure 8b and c, upper panels, lane 4) . Immunoblotting with the anti-p53 PAb421 monoclonal antibody, which recognizes an epitope within the C-terminus of p53, con®rmed equal loading of the GST-p53 proteins (Figure 8b and c, lower panels, lanes 3 and 4).
Discussion
This paper demonstrates that PKR physically associates with p53 in mouse, monkey, rat and human cells (Figures 1 ± 3) . The interaction of PKR with p53 is independent of cell transformation (Figure 1b) or treatment with IFN ( Figure 1b ) but is enhanced after IFN stimulation most likely as a result of upregulation of PKR protein (Figure 1 ). While the in vitro data suggest a direct interaction between PKR and p53, the possibility that the PKR/p53 complex formation is facilitated by other proteins in vivo cannot be excluded.
The interaction of PKR with p53 in vitro requires the N-terminal regulatory domain of PKR, which is important for its RNA-binding and dimerization activities (Clemens and Elia, 1997). However, the RNA-binding property of PKR appears to be dispensable for its interaction with p53 since a mutant form of PKR, which completely lacks RNA-binding capacity, is still capable of binding to p53 (Figure 4 ). In accord with this, treatment of cell extracts with RNaseA did not aect the interaction of PKR with p53 in vitro (data not shown). However, it should be noted that it is not known whether the binding of p53 to PKR modulates either the RNA-binding and/or dimerization capacity of PKR. In addition, further deletion analysis of the N-terminus of PKR did not . The GST-p53 fusion protein (a.a. 319 ± 393) was subjected to in vitro mutagenesis analysis to replace each of the seven serines with alanines. Equal amounts (250 ng) of the indicated puri®ed mutant GST-fusion proteins were subjected to phosphorylation by PKR in vitro. Phosphorylated GST-p53 fusion proteins were pulled down from the reaction mixtures with glutathione-sepharose and analysed by SDS ± 12% PAGE and autoradiography. As control, reactions without substrate (lanes 1 and 9) or with GST-protein only (lane 8) were used identify a speci®c primary sequence of PKR required for interaction with p53 (data not shown). This suggests that the p53-binding sites may be scattered through the N-terminus domain of PKR and/or the interaction may be dependent upon the conformation of either protein. Although the amount of PKR/p53 complex appears to be dependent on the conformation of p53 (Figure 3 ), it will be essential to solve the structure of PKR to verify any possible conformational requirements for its interaction with p53.
The mapping of the interaction sites has shown that the PKR/p53 complex formation requires the last 30 amino acids of the C-terminus of p53 ( Figure 5 ). The observation that the anti-p53 PAb421 antibody, which binds to the amino acids 371 ± 381 of human p53, is capable of co-immunoprecipitating the PKR/p53 complex (Figures 1 and 2) indicates that the binding of PKR to the C-terminus does not occlude the PAb421 epitope. Although the interaction of PKR with p53 requires the C-terminus of p53, we have observed a higher amount of PKR/p53 complex formation in cells expressing the tsp53 (val135) upon conditions that p53 acquires a wild type conformation (Figure 3) . Perhaps then PKR/p53 interaction is facilitated by other protein(s) whose function is dependent on p53 conformational changes. It is widely believed that the ability of p53 to bind speci®c DNA sequences is regulated by the C-terminal domain. For example, deletion of the last 30 amino acids of p53 gives rise to a form of the protein that is able to bind DNA constitutively (Hupp et al., 1992) . Similarly, addition of the anti-p53 PAb421 monoclonal antibody can stimulate p53 DNA binding (Hupp et al., 1992; Halazonetis et al., 1993) . However, the N-terminal domain of PKR did not lead to induction of p53 DNA binding in vitro (data not shown) indicating that the protein-protein interaction between PKR and p53 may not play a role in modulating p53 DNA-binding in vivo.
In addition to binding speci®c DNA sequences, p53 has been shown to catalyze the annealing of complementary single strands of DNA or RNA (Oberosler et al., 1993) . This was later shown to be regulated by the C-terminal domain of p53 (Brain and Jenkins, 1994; Balkalkin et al., 1995; Wu et al., 1995) . The C-terminal domain also regulates the ability of p53 to bind nonspeci®cally to many types of DNA (Wang et al., 1993; Balkalkin et al., 1994; Bayle et al., 1995; Lee et al., 1995; Reed et al., 1995) . Interestingly, these functions are mutually exclusive of the sequence -phosphorylated GST-p53 fusion proteins. GST-wtPKR was subjected to a kinase assay using 1 mM of cold ATP in the absence (lane 2) or presence (lane 4) of 250 ng of GST-p53 Cterminus (b) or GST-full length p53 (c). Kinase reactions were resolved on either SDS ± 12% PAGE (b) or SDS ± 10% PAGE (c) and transferred to PVDF membranes. Immunoblotting was performed ®rst with rabbit antisera to phosphoserine 392 (b and c, upper panels). The membranes were then stripped o and re-probed with the anti-p53 PAb421 monoclonal antibody (b and c, lower panels) to con®rm equal loading of p53 proteins. As controls, GST was used in place of GST-wtPKR (b and c, lanes 1 and 3) speci®c DNA binding capacity of p53. For example, addition of the anti-p53 PAb421 antibody not only stimulates sequence speci®c DNA binding but inhibits nonspeci®c DNA interactions and reannealing by p53 (Ko and Prives, 1996) . This suggests that the ability of p53 to interact with speci®c and non-speci®c DNA sequences, and to catalyze reannealing is regulated by conformational changes dictated by the C-terminal domain (Ko and Prives, 1996) . It is not known at this time whether the binding of PKR to the C-terminus domain of p53 plays a role in any of these p53 functions.
We have shown that PKR, either immunoprecipitated from whole cells extracts or expressed as a GST fusion protein can phosphorylate human p53 on serine 392 in vitro on GST fusion proteins encompassing full length p53 or the C-terminus of p53 (Figures 6 ± 8) . PKR phosphorylates eIF-2a to a greater extent than the C-terminus of p53 in vitro (Figure 8a ), indicating that eIF-2a has a higher anity as a substrate for PKR than the C-terminus of p53. We also observed that the C-terminus of p53 is a better substrate for PKR than full-length p53 (Figure 8b and c), indicating that ecient phosphorylation of full-length p53 in vitro by PKR might require that p53 be in a certain conformation. Although the N-terminus or the DNAbinding domains of p53 were not phosphorylated by PKR in vitro (data not shown), the possibility that PKR mediates phosphorylation of p53 on site(s) other than serine 392 cannot be ruled out entirely. Many kinases that phosphorylate p53 in vitro have been identi®ed (Steegenga et al., 1996) . However, in many cases, the conditions required for the kinases that phosphorylate p53 in vitro to function in the same capacity in vivo are not well understood. For instance, protein kinase C (PKC) has been previously found to phosphorylate p53 on serine 378 and stimulate its speci®c DNA-binding in vitro (Takenaka et al., 1995) . However, cells treated with the PKC activator phorbol-myristate-acetate (PMA) did not stimulate phosphorylation of p53 suggesting that PKC may not be responsible for p53 phosphorylation in vivo or that PMA treatment is not sucient to cause phosphorylation of p53 by PKC (Milne et al., 1996) . In analogy to PKC, the conditions that PKR induces p53 phosphorylation on serine 392 in vivo are not clear. Experiments with PKR 7/7 cells or cells expressing dominant negative PKR mutants using an antibody that speci®cally recognizes phosphoserine 389 of mouse p53 (Lu et al., 1998) were inconclusive due to the high background phosphorylation on serine 389 (data not shown). This background phosphorylation was observed even when cells were treated with the CKII speci®c inhibitor 5,6 dichloro-1-b-D-ribofuranosylbenzimidazole (data not shown). This suggests that there is a considerable redundancy of p53 serine 389 phosphorylation in vivo although its does not exclude the possibility of phosphorylation of a small fraction of p53 by PKR. This is supported by the observation that only a portion (*10%) of cellular p53 interacts with PKR in vivo (Figures 1 and 2) . Interestingly, phosphorylation of p53 on serine 392 induces sequences-speci®c DNA binding of p53 in vitro (Hupp et al., 1992) and is enhanced in cells in response to DNA damage induced by UV radiation (Lu et al., 1998) .
In addition to gene transcription, p53 has been implicated in regulation of mRNA translation (Ewen and Miller, 1996; Fu et al., 1996) . For example, p53 has been shown to regulate its own translation via the 5' untranslated region (UTR) of the mouse p53 mRNA (Mosner et al., 1995) or the 3' UTR of human p53 mRNA (Fu and Benchimol, 1997) . However, translation of mouse p53 may not be aected by PKR since p53 protein levels do not change in mouse cells lacking PKR (i.e. PKR 7/7 cells, Yang et al., 1995) or in mouse cells expressing dominant negative mutants of PKR (Koromilas et al., 1992; Meurs et al., 1993) . Phosphorylation of serine 389 has been shown to be required for mouse p53 to be covalently linked to 5.8S RNA, and this has been suggested to give p53 access to the ribosomal interface thereby allowing it to modulate protein synthesis (Fontoura et al., 1992 (Fontoura et al., , 1997 . One possible mechanism by which p53 regulates translation might involve binding to the 5' UTR of a particular mRNA thereby sterically preventing ribosome entry (Ewen and Miller, 1996) . The 5' UTR of mRNAs of many proto-oncogenes and cell growth regulating genes are relatively long and GC-rich, resulting in signi®cant predicted secondary structure, which might aect the translational regulation of such mRNAs (Geballe, 1996) . In fact, p53 has been shown to regulate the translation of the cyclin dependent kinase 4 (cdk4) and this requires the 5' UTR of the cdk4 mRNA (Ewen et al., 1995) . It is conceivable that RNA secondary structure could function as an activator of PKR resulting in a local phosphorylation of eIF-2a and inhibition of translation initiation (Clemens and Elia, 1997) . Although the PKR/p53 interaction can occur in the absence of RNA, it is possible that binding of PKR within the PKR/p53 complex to a speci®c RNA structure results in PKR activation and local phosphorylation of p53 and/or eIF-2a. Phosphorylation of p53 on serine 392 might target PKR/p53 complex to the ribosomal components of the translation machinery whereas phosphorylation of eIF-2a may then result in translation inhibition of a speci®c mRNA thus allowing both proteins to exhibit a speci®c function. Such local events are thought to be maintained in vivo by compartmentalization or anchoring of translation factors to cytoskeletal framework (Howe and Hershey, 1984) . The interaction between PKR and p53 may then provide a tentative as yet unidenti®ed link between the two proteins in the regulation of protein synthesis.
In conclusion, the data presented here demonstrate the interaction between PKR and p53 and provide strong evidence for its functionality in vitro. Further understanding of the basis of pKR/p53 interaction is likely to yield important insights into biological function of both proteins in regard to transcription, translation and regulation of signaling pathways that aect cell proliferation.
Materials and methods
Cell culture and transfections
COS-1 (ATCC CRL-1650), mouse embryo ®broblasts (MEFs) with PKR +/+ and PKR 7/7 genotype (Yang et al., 1995) and baby rat kidney (BRK) cells expressing the temperature sensitive (ts) mutant of p53 (val135) and adenovirus E1A and the E1B 19K proteins (Debbas and White, 1993) were grown in Dulbecco's modi®ed Eagle's medium (Life Technologies Inc.). HeLaS3 cells (ATCC CCL-2.2) were grown in RPMI 1640 (Life Technologies Inc.). Both media were supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, and penicillinstreptomycin (100 u/ml) with the exception of BRK cells, which were grown in 5% heat-inactivated fetal bovine serum (FBS).
For IFN treatment, MEFs were incubated overnight with 1000 IU/ml of murine IFN-a/b (Lee Biomolecules, CA, USA) whereas HeLaS3 cells were treated with 1000 IU/ml of human IFN-b (Lee Biomolecules, CA, USA). Transient transfections were accomplished using the calcium phosphate method (Sambrook et al., 1989) .
Plasmid construction and puri®cation of GST-fusion proteins
Transient transfections were performed with PKRK296R (Katze et al., 1991) and PKRD6 (Koromilas et al., 1992) that were subcloned into the ClaI/XbaI sites of the pEF plasmid (Mizushima and Nagata, 1990) .
For GST fusion proteins, full length wt human p53 and p53 deletion mutants encompassing the amino acids 1 ± 160, 160 ± 318 and 319 ± 393 cloned into pGEX-2T vector (Pharmacia Biotech) have been previously described (Chen et al., 1993) . The serine to alanine substitutions, and generation of deletion mutants encompassing the amino acids 319 ± 362 and 319 ± 337 was accomplished using the QuikChange Site Directed Mutagenesis Kit ( Full length GST-wtPKR and GST-PKRK296R was subcloned into the BamHI site of pGEX-2T. Deletion mutants encompassing the amino acids 1 ± 262 and 263 ± 551 were generated by amplifying the appropriate fragment by PCR using the following primers: for amino acids 1 ± 262, the , Green et al., 1995) was generated by amplifying the appropriate fragment from pCDNA3/neo-PKRLS9 template with the following primers: 5'-d[GGGG-GGATCCGCTGGTGATCTTTCAGCAGGTT-T]-3', and 5'-d[GGGGGA TCC TAA AAC CTCTTGTCCACAGTATAC]-3'. The PCR product was ligated into the BamHI site of pGEX-2T. All deoxynucleotides were purchased from Sheldon Biotechnology, Montreal, Canada.
All GST plasmids were transformed into the E. coli BL21 strain. Isopropyl-b-D-thiogalactopyranoside (IPTG) induction and puri®cation of GST-fusion proteins using glutathione-sepharose beads (Pharmacia) was performed as previously described (Frangioni and Neel, 1993) . All proteins were eluted using glutathione (pH 8.0) at a ®nal concentration of 5 mM and dialyzed against phosphate buered saline (PBS: 140 mM NaCl, 15 mM KH 2 PO4 (pH 7.2), and 2.7 mM KCl).
Cell extraction, immunoprecipitation and immunoblot analysis
Cells were washed with ice-cold PBS and lysed with ten volumes of lysis buer consisting of 10 mM Tris-Cl (pH 7.5), 100 mM KCl, 4 mM MgCl 2 , 1% Triton X-100, 1 mM dithiothreitol (DTT), 0.2 mM phenylmethylsulfonyl¯uoride (PMSF; Sigma) and 3 mg/ml aprotinin (Sigma), 1 mg/ml pepstatin (Sigma), and 1 mg/ml leupeptin (Sigma). The lysate was centrifuged at 10 000 g for 10 min, and the supernatant was used either for PKR autophosphorylation assays or detection of the PKR/p53 interaction.
To assay for PKR/p53 interaction, 0.5 mg of cell extracts were incubated with 1 mg of either anti-p53 or anti-PKR antibody for 4 h at 48C. Then, 50 ml of 50% suspension of protein A-Sepharose 4L (Pharmacia Biotech Inc.) was added, and incubation was continued for an additional 4 h at 48C under rotation. The sepharose beads were washed with 1 ml ice-cold lysis buer twice, 1 ml ice-cold lysis buer plus 500 mM NaCl twice and 1 ml ice-cold lysis buer once. Chemical coupling of anti-human PKR antibody (13B8-F9) to agarose beads was performed using the A-Gel Hz kit (Bio-Rad) according to manufacturer's speci®cations with a yield of 5 mg of antibody/1 ml of packed gel.
For immunoblot analysis, immunoprecipitates or whole cell extracts (50 mg of protein) were subjected to electrophoresis on sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred onto a polyvinylidene di¯uoride (PVDF) membrane (Immobilon P; Millipore) in 25 mM 190 mM glycine, and 20% (v/v) methanole for 1 h at 300 mA. The ®lter was ®rst blocked with 5% (w/v) non-fat dried skimmed milk powder in 16PBS for 1 h at room temperature and then incubated for 1 h at room temperature with 5% (w/v) non fat skim milk and 0.5% (v/v) Triton X-100 in 16PBS containing the following antibodies: mouse monoclonal antibodies against human PKR (13B8-F9; provided by A Darveau and G Barber), p53 (PAb421 or PAb1801, Calbiochem) or actin (clone C4, ICN); and rabbit polyclonal antibodies against mouse PKR (TIK), p53 (CM-1; Novocastra), or p21 (C-19, Santa Cruz). Blots were washed 36 with 16PBS ± 0.5% Triton X-100 and incubated with either horseradishperoxidase (HRP)-conjugated sheep anti-mouse or donkey anti-rabbit immunoglobulin (Amersham) for 1 h at room temperature. The blots were washed 36 with 16PBS ± 0.5% Triton X-100 and the proteins were visualized using enhanced chemiluminescence (ECL) according to the manufacturer's speci®cations (Amersham).
In vitro activation of PKR and phosphorylation of GST-p53 fusion proteins Fifty mg of protein extracts from IFN-b treated HeLaS3 cells were precleared with 1 mg mouse IgG 1 and protein G-agarose before immunoprecipitation with 1 mg of anti-human PKR (13B8-F9) antibody. Immunoprecipitates were suspended in kinase reaction buer [10 mM Tris-Cl (pH 7.7), 50 mM KCl, 2 mM MgCl 2 , 5 mM b-mercaptoethanol, 4 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, and 0.2 mM PMSF]. Reovirus dsRNA was then added to a ®nal concentration of 0.1 mg/ml and the reaction was incubated at 48C for 10 min. 250 ng of the appropriate GST fusion protein or 50 ng of puri®ed eIF-2a together with 1 mCi of [g-32 P]ATP (ICN) was then added. After incubation at 308C for 30 min, the reaction was stopped with an equal volume of 26Laemmli buer (Sambrook et al., 1989) and subjected to SDS ± 12% PAGE analysis and autoradiography. In some cases, after incubation the reactions were diluted ®vefold with ice-cold PBS, centrifuged at 10 000 g for 10 s, and GST-p53 fusion proteins were further pulled down from the supernatant with glutathione-sepharose beads (Pharmacia). These precipitates were then mixed with 26Laemmli SDS ± PAGE buer, and phosphorylated proteins were analysed by SDS ± 12% PAGE and autoradiography.
For in vitro kinase assays with recombinant PKR, puri®ed GST-wtPKR was added to kinase buer together with 250 ng of the appropriate fusion proteins and 1 mCi of [g-32 P]ATP or 1 mM of cold ATP (Pharmacia Biotech). After incubation for 30 min at 308C, the reaction was stopped by the addition of 26Laemmli buer and the reactions were resolved on SDS ± 10% or ± 12% PAGE. The gel was either dried and labeled proteins visualized by autoradiography or the proteins were transformed to a PVDF membrane and immunoblotted with rabbit antisera to phosphoserine 392 .
Phosphoamino acid analysis
For phosphoamino acid analysis, 32 P-labeled GST-fusion protein encompassing the C-terminus of p53 (a.a. 319 ± 393) was cleaved with thrombin, fractionated by SDS ± 15% PAGE and transferred onto a PVDF membrane. The 32 Plabeled p53 portion visualized by autoradiography was excised from the membrane, hydrolyzed with HCl and analysed by two-dimensional thin-layer chromatography as previously described (Boyle et al., 1991) .
In vitro transcription/translation and GST-pull down assays PKR and p53 proteins were synthesized in vitro using the TNT SP6/T7 in vitro transcription and translation system (Promega) and [ 35 S]methionine (41000 Ci/mmol; Amersham) according to manufacturer's speci®cations. Pulldown experiments were performed with *1 mg of the appropriate puri®ed GST-fusion protein and 35 S-labeled PKR or p53 as described elsewhere (Choubey and Lengyel, 1995) . Samples were subjected to SDS ± 10% PAGE and gels were treated with EN 3 HANCE (Dupont) according to the manufacturer's speci®cations before visualization by fluorography.
